


# New Biotherapeutics Product for the treatment of respiratory diseases

Identification of a bacterial strain that reduces inflammation

Probiotic – Asthma - Anti-inflammatory



#InnoverAvecINRAE



# New Biotherapeutics Product for the treatment of respiratory diseases

## Description

Chronic respiratory conditions pose a significant medical, social, and economic challenge. Current treatments based, are not always effective and can have adverse effects. Our patented research has revealed that some strains of *Enterococcus faecalis* (registered and protected) exhibits anti-inflammatory properties both in vitro and ex vivo, and it enhances the effectiveness of corticosteroids.

## Key advantages

- ▶ Natural alternative to anti-inflammatory drugs.
- ▶ Easy to produce.
- ▶ Safety addressed.
- ▶ Life biotherapy product or inactive product.

## Potential applications

- ▶ Treatment of allergic asthma in babies and in adult patients who do not respond well to corticosteroids.
- ▶ Prevention of other chronic respiratory conditions (allergy, chronic obstructive pulmonary disease, allergic rhinitis, ...).

## CONTACTS

INRAE Transfert – Alexis DELETOILE  
[alexis.deletoile@inrae.fr](mailto:alexis.deletoile@inrae.fr) - +33 (0)6 47 05 15 98  
 SATT Paris-Saclay – Kenza BELHAJ  
[kenza.belhaj@satt-paris-saclay.fr](mailto:kenza.belhaj@satt-paris-saclay.fr)



## Type of transfer

We are looking for an industrial partner to license the technology or for a licensing option with R&D program

## Technology Readiness Level

1 2 3 4 5 6 7 8 9

## Development stage

Characterization and validation of the bacterium has been done. The anti-inflammatory effects of *E. faecalis* have been demonstrated in vivo and ex vivo. An Investigational Medicinal Product has been submitted and validated by the ANSM (French regulatory Agency)



## Laboratory & Team

**Institut Micalis**  
 Centre INRAE Jouy-en-Josas

Muriel THOMAS  
 Researcher

Pascale SERROR  
 Researcher